Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free HIT Stock Alerts

Health In Tech (HIT) Financials

Health In Tech logo
$1.04 -0.03 (-2.80%)
As of 02:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Health In Tech

Annual Income Statements for Health In Tech

This table shows Health In Tech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 2.48 0.67 1.28
Consolidated Net Income / (Loss)		 3.96 0.67 1.28
Net Income / (Loss) Continuing Operations		 2.48 0.67 1.28
Total Pre-Tax Income 		3.42 0.89 1.67
Total Operating Income		 3.38 0.99 1.53
Total Gross Profit		 17 15 21
Total Revenue		 19 19 33
Operating Revenue		 19 19 33
Total Cost of Revenue		 2.30 4.05 12
Operating Cost of Revenue		 2.30 4.05 12
Total Operating Expenses		 13 14 19
Selling, General & Admin Expense		 8.08 8.48 14
Marketing Expense		 3.38 3.16 4.19
Research & Development Expense		 2.00 2.81 1.57
Total Other Income / (Expense), net		 0.04 -0.10 0.15
Interest Expense		 0.00 0.50 0.00
Interest & Investment Income		 0.04 0.12 0.41
Other Income / (Expense), net		 0.00 0.27 -0.26
Income Tax Expense		 0.95 0.22 0.40
Basic Earnings per Share		 $0.16 $0.01 $0.02
Weighted Average Basic Shares Outstanding		 51.77M 51.84M 55.84M
Diluted Earnings per Share		 $0.16 $0.01 $0.02
Weighted Average Diluted Shares Outstanding		 51.77M 53.66M 57.74M
Weighted Average Basic & Diluted Shares Outstanding		 - 54.61M 59.96M

Quarterly Income Statements for Health In Tech

This table shows Health In Tech's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 0.10 0.34 0.38 -0.14 0.50 0.63 0.45 -0.30 -1.59
Consolidated Net Income / (Loss)		 0.10 0.34 0.38 -0.14 0.50 0.63 0.45 -0.30 -1.59
Net Income / (Loss) Continuing Operations		 0.10 0.34 0.38 -0.14 0.50 0.63 0.45 -0.30 -1.59
Total Pre-Tax Income 		0.19 0.40 0.41 -0.11 0.68 0.83 0.60 -0.44 -2.07
Total Operating Income		 0.33 0.53 0.44 -0.32 0.48 0.73 0.49 -0.17 -2.16
Total Gross Profit		 4.14 4.03 3.48 3.80 5.36 6.31 5.14 4.13 4.51
Total Revenue		 5.12 5.00 4.46 4.90 8.01 9.31 8.49 7.51 8.77
Operating Revenue		 5.12 5.00 4.46 4.90 8.01 9.31 8.49 7.51 8.77
Total Cost of Revenue		 0.99 0.97 0.98 1.11 2.66 3.00 3.35 3.38 4.26
Operating Cost of Revenue		 0.99 0.97 0.98 1.11 2.66 3.00 3.35 3.38 4.26
Total Operating Expenses		 3.80 3.49 3.04 4.11 4.87 5.58 4.65 4.30 6.67
Selling, General & Admin Expense		 2.00 1.82 1.81 2.85 3.25 3.78 3.45 3.18 3.46
Marketing Expense		 1.04 0.97 0.51 0.63 1.09 1.23 0.96 0.91 2.29
Research & Development Expense		 0.76 0.70 0.72 0.63 0.54 0.58 0.24 0.21 0.92
Total Other Income / (Expense), net		 -0.14 -0.13 -0.03 0.21 0.20 0.11 0.11 -0.27 0.09
Interest & Investment Income		 0.02 0.03 0.04 0.03 0.09 0.11 0.11 0.10 0.07
Other Income / (Expense), net		 0.00 0.00 0.09 0.18 0.12 0.00 -0.01 -0.38 0.02
Income Tax Expense		 0.09 0.06 0.03 0.03 0.19 0.20 0.15 -0.14 -0.48
Basic Earnings per Share		 $0.00 $0.01 $0.01 ($0.01) $0.01 $0.01 $0.01 ($0.01) ($0.03)
Weighted Average Basic Shares Outstanding		 51.77M 51.77M 51.77M 51.84M 54.62M 55.38M 56.43M 55.84M 57.35M
Diluted Earnings per Share		 $0.00 $0.01 $0.01 ($0.01) $0.01 $0.01 $0.01 ($0.01) ($0.03)
Weighted Average Diluted Shares Outstanding		 51.77M 51.77M 51.77M 53.66M 57.00M 55.63M 58.77M 57.74M 57.35M
Weighted Average Basic & Diluted Shares Outstanding		 - - - 54.61M 54.67M 56.39M 56.91M 59.96M 65.53M

Annual Cash Flow Statements for Health In Tech

This table details how cash moves in and out of Health In Tech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.93 5.43 -0.18
Net Cash From Operating Activities		 1.53 2.18 3.13
Net Cash From Continuing Operating Activities		 1.53 2.17 3.13
Net Income / (Loss) Continuing Operations		 3.96 0.67 1.28
Consolidated Net Income / (Loss)		 3.96 0.67 1.28
Depreciation Expense		 0.34 0.54 0.90
Amortization Expense		 0.00 0.50 0.00
Non-Cash Adjustments To Reconcile Net Income		 -0.02 0.41 5.76
Changes in Operating Assets and Liabilities, net		 -2.75 0.06 -4.80
Net Cash From Investing Activities		 -1.94 -0.84 -3.13
Net Cash From Continuing Investing Activities		 -1.94 -0.84 -3.13
Purchase of Property, Plant & Equipment		 -1.14 -0.90 -3.19
Sale and/or Maturity of Investments		 0.00 0.06 0.06
Net Cash From Financing Activities		 1.34 4.09 -0.19
Net Cash From Continuing Financing Activities		 1.34 4.09 -0.19
Repayment of Debt		 0.00 -2.15 0.00
Issuance of Common Equity		 0.00 8.21 0.00
Other Financing Activities, net		 -0.26 -1.98 -0.19
Cash Interest Paid		 0.00 0.00 0.00
Cash Income Taxes Paid		 0.48 0.56 0.83

Quarterly Cash Flow Statements for Health In Tech

This table details how cash moves in and out of Health In Tech's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.06 0.80 -0.42 6.10 -0.27 0.56 -0.11 -0.35 2.66
Net Cash From Operating Activities		 -0.68 1.27 2.12 -0.53 0.53 1.48 0.67 0.45 -3.32
Net Cash From Continuing Operating Activities		 -0.68 1.27 2.12 -0.53 0.53 1.48 0.67 0.45 -3.32
Net Income / (Loss) Continuing Operations		 0.10 0.34 0.38 -0.14 0.50 0.63 0.45 -0.30 -1.59
Consolidated Net Income / (Loss)		 0.10 0.34 0.38 -0.14 0.50 0.63 0.45 -0.30 -1.59
Depreciation Expense		 0.13 0.13 0.14 0.14 0.14 0.14 0.22 0.41 0.40
Non-Cash Adjustments To Reconcile Net Income		 -0.02 -0.02 -0.02 0.45 1.26 0.87 1.69 1.94 0.46
Changes in Operating Assets and Liabilities, net		 -1.07 0.65 1.46 -0.98 -1.36 -0.16 -1.68 -1.60 -2.59
Net Cash From Investing Activities		 -0.13 -0.09 -0.07 -0.54 -0.70 -0.91 -0.74 -0.77 -0.36
Net Cash From Continuing Investing Activities		 -0.13 -0.09 -0.07 -0.54 -0.70 -0.91 -0.74 -0.77 -0.36
Purchase of Property, Plant & Equipment		 -0.13 -0.09 -0.07 -0.61 -0.70 -0.91 -0.74 -0.83 -0.36
Net Cash From Financing Activities		 -0.24 -0.37 -2.47 7.18 -0.10 -0.01 -0.04 -0.04 6.34
Net Cash From Continuing Financing Activities		 -0.24 -0.37 -2.47 7.18 -0.10 -0.01 -0.04 -0.04 6.34
Issuance of Common Equity		 - - - - 0.00 - - - 6.38
Other Financing Activities, net		 -0.24 -0.37 -0.32 -1.04 -0.10 -0.01 -0.04 -0.04 -0.04
Cash Interest Paid		 0.00 - - - 0.00 - - - 0.00
Cash Income Taxes Paid		 0.04 0.29 0.02 0.22 0.00 0.63 0.20 0.01 0.00

Annual Balance Sheets for Health In Tech

This table presents Health In Tech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 12 16 23
Total Current Assets		 6.86 11 16
Cash & Equivalents		 2.42 7.85 7.67
Note & Lease Receivable		 - 0.00 0.82
Accounts Receivable		 3.92 2.15 4.22
Prepaid Expenses		 0.26 0.79 3.28
Plant, Property, & Equipment, net		 0.00 0.00 0.00
Total Noncurrent Assets		 4.91 4.98 6.93
Intangible Assets		 3.56 3.96 6.53
Other Noncurrent Operating Assets		 0.53 0.21 0.40
Total Liabilities & Shareholders' Equity		 12 16 23
Total Liabilities		 5.41 2.60 5.98
Total Current Liabilities		 4.78 2.13 5.16
Accounts Payable		 2.62 1.86 4.19
Other Current Liabilities		 0.06 0.07 0.97
Total Noncurrent Liabilities		 0.63 0.47 0.82
Noncurrent Deferred & Payable Income Tax Liabilities		 0.42 0.33 0.76
Other Noncurrent Operating Liabilities		 0.21 0.14 0.06
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.09 13 17
Total Preferred & Common Equity		 6.09 13 17
Total Common Equity		 6.09 13 17
Common Stock		 2.82 9.23 12
Retained Earnings		 3.27 3.94 5.22

Quarterly Balance Sheets for Health In Tech

This table presents Health In Tech's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 21 22 23 29
Total Current Assets		 16 15 15 22
Cash & Equivalents		 7.58 8.14 8.02 10
Note & Lease Receivable		 - - - 0.83
Accounts Receivable		 6.10 5.14 4.74 8.07
Prepaid Expenses		 1.80 1.51 2.12 2.86
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 5.76 7.32 7.71 6.88
Intangible Assets		 4.74 5.52 6.18 6.71
Other Noncurrent Operating Assets		 0.19 0.96 0.66 0.17
Total Liabilities & Shareholders' Equity		 21 22 23 29
Total Liabilities		 7.17 5.75 5.60 7.36
Total Current Liabilities		 6.75 5.39 5.24 7.05
Accounts Payable		 5.48 4.33 4.30 6.97
Other Current Liabilities		 0.85 1.03 0.94 0.08
Total Noncurrent Liabilities		 0.42 0.37 0.36 0.32
Noncurrent Deferred & Payable Income Tax Liabilities		 0.29 0.26 0.27 0.27
Other Noncurrent Operating Liabilities		 0.12 0.10 0.08 0.04
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 16 17 22
Total Preferred & Common Equity		 14 16 17 22
Total Common Equity		 14 16 17 22
Common Stock		 9.72 11 12 18
Retained Earnings		 4.44 5.07 5.52 3.63

Annual Metrics And Ratios for Health In Tech

This table displays calculated financial ratios and metrics derived from Health In Tech's official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 0.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00
Growth Metrics		 - - -
Revenue Growth		 0.00% 1.77% 70.99%
EBITDA Growth		 0.00% -38.29% -5.76%
EBIT Growth		 0.00% -62.72% 0.25%
NOPAT Growth		 0.00% -69.51% 56.38%
Net Income Growth		 0.00% -83.06% 90.74%
EPS Growth		 0.00% -93.75% 100.00%
Operating Cash Flow Growth		 0.00% 42.34% 44.00%
Free Cash Flow Firm Growth		 0.00% 0.00% -469.39%
Invested Capital Growth		 0.00% -0.13% 74.28%
Revenue Q/Q Growth		 0.00% 0.00% 8.48%
EBITDA Q/Q Growth		 0.00% 0.00% -5.84%
EBIT Q/Q Growth		 0.00% 0.00% -24.44%
NOPAT Q/Q Growth		 0.00% 0.00% 17.90%
Net Income Q/Q Growth		 0.00% 0.00% -11.02%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 45.66%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 3.37%
Profitability Metrics		 - - -
Gross Margin		 87.97% 79.21% 62.82%
EBITDA Margin		 19.44% 11.79% 6.50%
Operating Margin		 17.66% 5.08% 4.59%
EBIT Margin		 17.66% 6.47% 3.79%
Profit (Net Income) Margin		 20.67% 3.44% 3.84%
Tax Burden Percent		 115.66% 75.42% 76.39%
Interest Burden Percent		 101.15% 70.49% 132.42%
Effective Tax Rate		 27.62% 24.58% 23.61%
Return on Invested Capital (ROIC)		 45.97% 14.02% 16.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -150.99% 15.79% 14.58%
Return on Net Nonoperating Assets (RNNOA)		 18.99% -7.06% -7.56%
Return on Equity (ROE)		 64.96% 6.96% 8.45%
Cash Return on Invested Capital (CROIC)		 0.00% 14.16% -38.16%
Operating Return on Assets (OROA)		 29.41% 9.25% 6.51%
Return on Assets (ROA)		 34.41% 4.92% 6.58%
Return on Common Equity (ROCE)		 64.96% 6.96% 8.45%
Return on Equity Simple (ROE_SIMPLE)		 64.96% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 2.45 0.75 1.17
NOPAT Margin		 12.79% 3.83% 3.50%
Net Nonoperating Expense Percent (NNEP)		 196.95% -1.77% 1.42%
Return On Investment Capital (ROIC_SIMPLE)		 31.62% 5.67% 6.82%
Cost of Revenue to Revenue		 12.03% 20.79% 37.18%
SG&A Expenses to Revenue		 42.19% 43.49% 40.97%
R&D to Revenue		 10.47% 14.44% 4.71%
Operating Expenses to Revenue		 70.31% 74.13% 58.24%
Earnings before Interest and Taxes (EBIT)		 3.38 1.26 1.26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.72 2.30 2.16
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.51 21.82 5.37
Price to Tangible Book Value (P/TBV)		 3.63 31.21 8.68
Price to Revenue (P/Rev)		 0.48 14.74 2.75
Price to Earnings (P/E)		 3.71 428.60 71.79
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 26.92% 0.23% 1.39%
Enterprise Value to Invested Capital (EV/IC)		 1.58 52.54 9.08
Enterprise Value to Revenue (EV/Rev)		 0.44 14.34 2.52
Enterprise Value to EBITDA (EV/EBITDA)		 2.27 121.67 38.87
Enterprise Value to EBIT (EV/EBIT)		 2.49 221.64 66.55
Enterprise Value to NOPAT (EV/NOPAT)		 3.44 374.39 72.07
Enterprise Value to Operating Cash Flow (EV/OCF)		 5.52 128.44 26.85
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 370.87 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.27 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.13 -0.45 -0.52
Leverage Ratio		 1.89 1.42 1.28
Compound Leverage Factor		 1.91 1.00 1.70
Debt to Total Capital		 21.31% 0.00% 0.00%
Short-Term Debt to Total Capital		 21.31% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 78.69% 100.00% 100.00%
Debt to EBITDA		 0.44 0.00 0.00
Net Debt to EBITDA		 -0.21 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.67 0.00 0.00
Net Debt to NOPAT		 -0.31 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 4.27 68.84 11.73
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 1.43 5.06 3.13
Quick Ratio		 1.32 4.69 2.46
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.75 -2.78
Operating Cash Flow to CapEx		 133.60% 241.60% 98.24%
Free Cash Flow to Firm to Interest Expense		 0.00 1.52 0.00
Operating Cash Flow to Interest Expense		 745.07 4.40 0.00
Operating Cash Flow Less CapEx to Interest Expense		 187.39 2.58 0.00
Efficiency Ratios		 - - -
Asset Turnover		 1.66 1.43 1.72
Accounts Receivable Turnover		 4.89 6.43 10.46
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.88 1.81 4.10
Days Sales Outstanding (DSO)		 74.65 56.78 34.89
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 415.23 201.80 89.08
Cash Conversion Cycle (CCC)		 -340.58 -145.02 -54.19
Capital & Investment Metrics		 - - -
Invested Capital		 5.33 5.32 9.27
Invested Capital Turnover		 3.60 3.66 4.57
Increase / (Decrease) in Invested Capital		 0.00 -0.01 3.95
Enterprise Value (EV)		 8.43 280 84
Market Capitalization		 9.20 287 92
Book Value per Share		 $0.12 $0.25 $0.31
Tangible Book Value per Share		 $0.05 $0.18 $0.19
Total Capital		 7.74 13 17
Total Debt		 1.65 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -0.77 -7.85 -7.67
Capital Expenditures (CapEx)		 1.14 0.90 3.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.31 0.80 3.33
Debt-free Net Working Capital (DFNWC)		 3.73 8.65 11
Net Working Capital (NWC)		 2.08 8.65 11
Net Nonoperating Expense (NNE)		 -1.51 0.08 -0.11
Net Nonoperating Obligations (NNO)		 -0.77 -7.85 -7.84
Total Depreciation and Amortization (D&A)		 0.34 1.04 0.90
Debt-free, Cash-free Net Working Capital to Revenue		 6.85% 4.12% 10.01%
Debt-free Net Working Capital to Revenue		 19.47% 44.39% 33.02%
Net Working Capital to Revenue		 10.85% 44.39% 33.02%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 $0.01 $0.02
Adjusted Weighted Average Basic Shares Outstanding		 0.00 51.84M 55.84M
Adjusted Diluted Earnings per Share		 $0.00 $0.01 $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 53.66M 57.74M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 54.61M 59.96M
Normalized Net Operating Profit after Tax (NOPAT)		 2.45 0.75 1.17
Normalized NOPAT Margin		 12.79% 3.83% 3.50%
Pre Tax Income Margin		 17.87% 4.56% 5.02%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 1,648.68 2.55 0.00
NOPAT to Interest Expense		 1,193.26 1.51 0.00
EBIT Less CapEx to Interest Expense		 1,091.00 0.73 0.00
NOPAT Less CapEx to Interest Expense		 635.58 -0.31 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 1.12% 0.00% 0.00%
Augmented Payout Ratio		 1.12% 0.00% 0.00%

Quarterly Metrics And Ratios for Health In Tech

This table displays calculated financial ratios and metrics derived from Health In Tech's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
DEI Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 56.39% 86.18% 90.41% 53.09% 9.44%
EBITDA Growth		 0.00% 0.00% 0.00% 0.00% 16.27% 3.15% -15.27% -3,792.91% -335.68%
EBIT Growth		 0.00% 0.00% 0.00% 0.00% 80.21% 35.54% -8.39% -293.06% -456.53%
NOPAT Growth		 0.00% 0.00% 0.00% 0.00% 100.88% 21.78% -8.38% 46.00% -531.44%
Net Income Growth		 0.00% 0.00% 0.00% 0.00% 395.93% 86.57% 20.23% -109.89% -418.55%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -400.00%
Operating Cash Flow Growth		 0.00% 0.00% 0.00% 0.00% 177.53% 16.95% -68.22% 184.95% -729.42%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.45%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 74.28% 73.66%
Revenue Q/Q Growth		 0.00% -2.39% -10.87% 9.99% 63.42% 16.21% -8.84% -11.56% 16.82%
EBITDA Q/Q Growth		 0.00% 32.03% -0.10% -100.42% 20,869.71% 17.14% -17.95% -119.50% -1,157.42%
EBIT Q/Q Growth		 0.00% 60.92% -0.31% -126.16% 529.36% 21.04% -32.62% -212.26% -289.46%
NOPAT Q/Q Growth		 0.00% 158.51% -9.94% -154.57% 258.13% 56.72% -32.25% -132.16% -1,163.46%
Net Income Q/Q Growth		 0.00% 236.20% 11.27% -138.33% 445.88% 26.48% -28.30% -166.91% -424.95%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -200.00% 200.00% 0.00% 0.00% -200.00% -200.00%
Operating Cash Flow Q/Q Growth		 0.00% 286.20% 67.47% -125.04% 199.28% 180.89% -54.50% -33.05% -835.63%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -24.84% -12.09% 52.65% -54.61%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 22.08% 26.56% 9.13% 3.37% 21.64%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 80.68% 80.52% 78.03% 77.43% 66.82% 67.75% 60.59% 54.99% 51.41%
EBITDA Margin		 12.34% 16.69% 18.70% -0.07% 9.17% 9.24% 8.32% -1.83% -19.75%
Operating Margin		 6.49% 10.69% 9.84% -6.45% 6.00% 7.78% 5.81% -2.27% -24.60%
EBIT Margin		 6.49% 10.69% 11.96% -2.84% 7.47% 7.78% 5.75% -7.30% -24.35%
Profit (Net Income) Margin		 1.96% 6.76% 8.43% -2.94% 6.22% 6.77% 5.33% -4.03% -18.11%
Tax Burden Percent		 52.44% 84.23% 92.46% 130.16% 72.85% 75.68% 75.33% 68.18% 76.79%
Interest Burden Percent		 57.68% 75.01% 76.27% 79.38% 114.25% 114.92% 122.86% 80.92% 96.84%
Effective Tax Rate		 47.56% 15.77% 7.54% 0.00% 27.15% 24.32% 24.67% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -16.54% 30.11% 38.27% 30.00% -7.27% -66.06%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -17.53% 26.24% 36.27% 28.04% -4.94% -65.20%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 10.45% -14.21% -18.12% -13.38% 2.56% 32.80%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -6.10% 15.91% 20.15% 16.62% -4.71% -33.26%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 14.17% 0.00% 0.00% 0.00% -38.16% -62.58%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -4.07% 7.84% 9.37% 7.77% -12.53% -33.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -4.20% 6.53% 8.15% 7.19% -6.91% -24.54%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -6.10% 15.91% 20.15% 16.62% -4.71% -33.26%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.17 0.45 0.41 -0.22 0.35 0.55 0.37 -0.12 -1.51
NOPAT Margin		 3.40% 9.01% 9.10% -4.51% 4.37% 5.89% 4.38% -1.59% -17.22%
Net Nonoperating Expense Percent (NNEP)		 0.00% 0.00% 0.00% 0.98% 3.87% 2.00% 1.96% -2.33% -0.86%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -1.68% 2.47% 3.34% 2.17% -0.70% -6.99%
Cost of Revenue to Revenue		 19.32% 19.48% 21.97% 22.57% 33.18% 32.25% 39.41% 45.01% 48.59%
SG&A Expenses to Revenue		 39.01% 36.32% 40.67% 58.07% 40.51% 40.54% 40.66% 42.35% 39.39%
R&D to Revenue		 14.83% 14.03% 16.11% 12.92% 6.71% 6.26% 2.78% 2.84% 10.49%
Operating Expenses to Revenue		 74.20% 69.82% 68.19% 83.88% 60.82% 59.96% 54.77% 57.26% 76.01%
Earnings before Interest and Taxes (EBIT)		 0.33 0.53 0.53 -0.14 0.60 0.73 0.49 -0.55 -2.14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.63 0.83 0.83 -0.00 0.74 0.86 0.71 -0.14 -1.73
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 21.82 2.66 2.98 11.00 5.37 3.85
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 31.21 4.00 4.49 17.19 8.68 5.58
Price to Revenue (P/Rev)		 0.00 0.00 0.00 14.74 1.69 1.83 6.14 2.75 2.44
Price to Earnings (P/E)		 0.00 0.00 0.00 428.60 35.30 35.97 131.27 71.79 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.23% 2.83% 2.78% 0.76% 1.39% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 52.54 4.64 4.97 20.14 9.08 6.46
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 14.34 1.35 1.53 5.88 2.52 2.14
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 121.67 14.56 16.82 78.57 38.87 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 221.64 19.73 23.76 107.97 66.55 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 374.39 34.24 40.95 182.42 72.07 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 128.44 8.91 11.34 83.96 26.85 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.00 0.00 -0.60 -0.54 -0.50 -0.48 -0.52 -0.50
Leverage Ratio		 0.00 0.00 0.00 1.42 1.51 1.35 1.33 1.28 1.41
Compound Leverage Factor		 0.00 0.00 0.00 1.12 1.72 1.55 1.63 1.04 1.36
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 68.54 5.09 7.25 22.50 11.47 8.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 0.00 0.00 0.00 5.06 2.31 2.76 2.87 3.13 3.13
Quick Ratio		 0.00 0.00 0.00 4.69 2.02 2.46 2.44 2.46 2.73
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 0.00 0.00 0.00 -6.14 -7.67 -8.60 -4.07 -6.29
Operating Cash Flow to CapEx		 -509.93% 1,347.93% 3,152.66% -87.63% 74.96% 162.80% 90.49% 54.25% -916.59%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -4.12 7.68 12.85 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.93 7.11 12.45 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 1.43 1.05 1.20 1.35 1.72 1.36
Accounts Receivable Turnover		 0.00 0.00 0.00 6.43 3.67 5.20 6.48 10.46 4.81
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 1.81 1.04 1.79 2.36 4.10 2.25
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 56.78 99.49 70.23 56.31 34.89 75.85
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 201.80 349.55 203.80 154.97 89.08 162.35
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 -145.02 -250.06 -133.57 -98.66 -54.19 -86.49
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 0.00 0.00 0.00 5.32 6.49 8.22 8.97 9.27 11
Invested Capital Turnover		 0.00 0.00 0.00 3.66 6.89 6.50 6.85 4.57 3.84
Increase / (Decrease) in Invested Capital		 0.00 0.00 0.00 0.00 6.49 8.22 8.97 3.95 4.78
Enterprise Value (EV)		 0.00 0.00 0.00 280 30 41 181 84 73
Market Capitalization		 9.20 9.20 9.20 287 38 49 189 92 83
Book Value per Share		 $0.00 $0.00 $0.00 $0.25 $0.26 $0.30 $0.30 $0.31 $0.38
Tangible Book Value per Share		 $0.00 $0.00 $0.00 $0.18 $0.17 $0.20 $0.19 $0.19 $0.26
Total Capital		 0.00 0.00 0.00 13 14 16 17 17 22
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 0.00 0.00 -7.85 -7.58 -8.14 -8.02 -7.67 -10
Capital Expenditures (CapEx)		 0.13 0.09 0.07 0.61 0.70 0.91 0.74 0.83 0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.00 0.00 0.80 1.24 1.33 1.79 3.33 4.72
Debt-free Net Working Capital (DFNWC)		 0.00 0.00 0.00 8.65 8.82 9.46 9.81 11 15
Net Working Capital (NWC)		 0.00 0.00 0.00 8.65 8.82 9.46 9.81 11 15
Net Nonoperating Expense (NNE)		 0.07 0.11 0.03 -0.08 -0.15 -0.08 -0.08 0.18 0.08
Net Nonoperating Obligations (NNO)		 0.00 0.00 0.00 -7.85 -7.67 -8.20 -8.19 -7.84 -10
Total Depreciation and Amortization (D&A)		 0.30 0.30 0.30 0.14 0.14 0.14 0.22 0.41 0.40
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 4.12% 5.55% 4.97% 5.81% 10.01% 13.84%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 44.39% 39.40% 35.46% 31.93% 33.02% 44.13%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 44.39% 39.40% 35.46% 31.93% 33.02% 44.13%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.01) $0.01 $0.01 $0.01 ($0.01) ($0.03)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 51.84M 54.62M 55.38M 56.43M 55.84M 57.35M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.01) $0.01 $0.01 $0.01 ($0.01) ($0.03)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 53.66M 57.00M 55.63M 58.77M 57.74M 57.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 54.61M 54.67M 56.39M 56.91M 59.96M 65.53M
Normalized Net Operating Profit after Tax (NOPAT)		 0.17 0.45 0.41 -0.22 0.35 0.55 0.37 -0.12 -1.51
Normalized NOPAT Margin		 3.40% 9.01% 9.10% -4.51% 4.37% 5.89% 4.38% -1.59% -17.22%
Pre Tax Income Margin		 3.74% 8.02% 9.12% -2.26% 8.54% 8.95% 7.07% -5.91% -23.58%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 2.01 3.24 3.23 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 1.06 2.73 2.46 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 1.21 2.67 2.82 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.25 2.16 2.05 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Health In Tech (NASDAQ: HIT) showed a sharp turnaround in 2025 after a weak start to 2024, but the latest quarter also highlights some important risk factors for investors to watch. Revenue continued to grow year over year, profitability improved meaningfully through most of 2025, and the company ended Q1 2026 with a strong cash balance. At the same time, operating cash flow turned negative in the latest quarter, operating expenses re-accelerated, and accounts payable remained elevated, which suggests working-capital pressure.

  • Revenue growth remains solid. Q1 2026 revenue rose to $8.8 million from $8.0 million in Q1 2025, while the company also posted higher revenue in most 2025 quarters versus 2024.
  • Gross profit expanded year over year. Q1 2026 gross profit was $4.5 million, up from $4.1 million in Q1 2025, showing continued top-line leverage.
  • Balance sheet cash increased. Cash and equivalents climbed to $10.3 million in Q1 2026 from $8.0 million at the end of Q3 2025.
  • Equity financing boosted liquidity. The company raised $6.4 million from common equity issuance in Q1 2026, helping offset operating and investing cash outflows.
  • Net income was positive in several recent quarters. HIT posted profits in Q2 and Q3 2025, and only a modest loss in Q4 2025 before widening to a loss in Q1 2026.
  • Operating cash flow was strong in 2025 until year-end. The company generated $1.5 million of operating cash flow in Q2 2025 and $674,000 in Q3 2025, a notable improvement versus early 2024.
  • Q1 2026 included a large non-cash adjustment burden. Net income of negative $1.6 million was helped by $0.9 million of non-cash adjustments, indicating earnings still rely on accounting add-backs.
  • Share count has increased. Basic weighted average shares rose to 57.4 million in Q1 2026 from 54.6 million in Q1 2025, which can dilute per-share value.
  • The company continues to invest in intangibles and receivables-related assets. Intangible assets increased to $6.7 million in Q1 2026, while accounts receivable remained sizable at $8.1 million.
  • Operating cash flow turned negative in Q1 2026. Cash from operations fell to negative $3.3 million, down from positive $451,000 in Q4 2025 and well below 2025’s stronger quarters.
  • Operating expenses jumped sharply in the latest quarter. Total operating expenses rose to $6.7 million in Q1 2026 from $4.3 million in Q4 2025, pulling operating income back into the red.
  • Marketing spend surged. Marketing expense increased to $2.3 million in Q1 2026 from $0.9 million in Q4 2025, which pressured margins.
  • Accounts payable stayed high. Payables were $7.0 million in Q1 2026, nearly matching total current liabilities and suggesting ongoing working-capital strain.
  • Recent profitability was not consistent. After turning profitable in Q2 and Q3 2025, HIT slipped back to a loss in Q4 2025 and Q1 2026.
  • Capital spending remains a cash use. The company spent $362,000 on property and equipment in Q1 2026, adding to already negative free-cash-flow pressure.

Bottom line: Health In Tech has made clear progress versus early 2024, with stronger revenue and periods of profitability in 2025. But the latest quarter shows that earnings and cash generation remain volatile. Investors should watch whether revenue growth can keep pace with higher spending, and whether the company can return to positive operating cash flow without relying on additional equity financing.

07/17/26 02:00 PM ETAI Generated. May Contain Errors.

Health In Tech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Health In Tech's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Health In Tech's net income appears to be on a downward trend, with a most recent value of $1.28 million in 2025, falling from $3.96 million in 2023. The previous period was $670.48 thousand in 2024. View Health In Tech's forecast to see where analysts expect Health In Tech to go next.

Health In Tech's total operating income in 2025 was $1.53 million, based on the following breakdown:
  • Total Gross Profit: $20.94 million
  • Total Operating Expenses: $19.41 million

Over the last 2 years, Health In Tech's total revenue changed from $19.15 million in 2023 to $33.33 million in 2025, a change of 74.0%.

Health In Tech's total liabilities were at $5.98 million at the end of 2025, a 130.0% increase from 2024, and a 10.5% increase since 2023.

In the past 2 years, Health In Tech's cash and equivalents has ranged from $2.42 million in 2023 to $7.85 million in 2024, and is currently $7.67 million as of their latest financial filing in 2025.

Over the last 2 years, Health In Tech's book value per share changed from 0.12 in 2023 to 0.31 in 2025, a change of 160.3%.


Related Companies

Financial statements for NASDAQ:HIT last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel